on 13 Jun 2024
Last Applicant/ Owned by
One Central Square
Cardiff
CF101FS
Serial Number
97686098 filed on 21st Nov 2022
Registration Number
N/A
Correspondent Address
NEW YORK, NY 10111
UNITED STATES
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Scientific research for medical purposes, namely, the research and development of pharmaceutical preparations for the treatment of respiratory conditions and disease, in particular, chronic obstructive pulmonary disease, cystic fibrosis and asthma Medical treatment services in the field of respiratory conditions and disease, namely, chronic obstructive pulmonary disease, cystic fibrosis and asthm Read More
Medical treatment services in the field of respiratory conditions and disease, namely, chronic obstructive pulmonary disease, cystic fibrosis and asthma; provision of medical information and services in the field of respiratory conditions and disease, namely, chronic obstructive pulmonary disease, cystic fibrosis and asthma
N/A
N/A
Scientific research for medical purposes, namely, the research and development of pharmaceutical preparations for the treatment of respiratory conditions and disease, in particular, chronic obstructive pulmonary disease, cystic fibrosis and asthma
N/A
N/A
Pharmaceutical preparations and substances for the treatment of respiratory conditions and disease, namely, chronic obstructive pulmonary disease, cystic fibrosis and asthma
N/A
N/A
No 97686098
No Service Mark
No 091938.139
Yes
No
No
Yes
No
No
No
No
26.17.09 -
Curved line(s), band(s) or bar(s)
Status Date | Action Taken |
---|---|
13th Jun 2024 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION |
13th Jun 2024 | ABANDONMENT - AFTER PUBLICATION |
12th Jun 2024 | TEAS EXPRESS ABANDONMENT RECEIVED |
11th Jun 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
11th Jun 2024 | PUBLISHED FOR OPPOSITION |
22nd May 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
09th May 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
25th Oct 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
25th Oct 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
25th Oct 2023 | ASSIGNED TO LIE |